IL42418A - An osmotic device for dispensing an active agent at a controlled rate - Google Patents

An osmotic device for dispensing an active agent at a controlled rate

Info

Publication number
IL42418A
IL42418A IL42418A IL4241873A IL42418A IL 42418 A IL42418 A IL 42418A IL 42418 A IL42418 A IL 42418A IL 4241873 A IL4241873 A IL 4241873A IL 42418 A IL42418 A IL 42418A
Authority
IL
Israel
Prior art keywords
dispensing
active agent
controlled rate
osmotic device
osmotic
Prior art date
Application number
IL42418A
Other languages
English (en)
Other versions
IL42418A0 (en
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL42418A0 publication Critical patent/IL42418A0/xx
Publication of IL42418A publication Critical patent/IL42418A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A61F6/142—Wirelike structures, e.g. loops, rings, spirals
    • A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
IL42418A 1972-06-05 1973-05-31 An osmotic device for dispensing an active agent at a controlled rate IL42418A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00259469A US3845770A (en) 1972-06-05 1972-06-05 Osmatic dispensing device for releasing beneficial agent

Publications (2)

Publication Number Publication Date
IL42418A0 IL42418A0 (en) 1973-07-30
IL42418A true IL42418A (en) 1975-07-28

Family

ID=22985088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL42418A IL42418A (en) 1972-06-05 1973-05-31 An osmotic device for dispensing an active agent at a controlled rate

Country Status (12)

Country Link
US (1) US3845770A (2)
JP (1) JPS596843B2 (2)
AR (1) AR199301A1 (2)
BR (1) BR7304196D0 (2)
CH (1) CH578464A5 (2)
ES (1) ES415568A1 (2)
FR (1) FR2188568A5 (2)
GB (1) GB1415210A (2)
IE (1) IE39952B1 (2)
IL (1) IL42418A (2)
NL (1) NL163721C (2)
ZA (1) ZA733734B (2)

Families Citing this family (2146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3996933A (en) * 1972-10-02 1976-12-14 Morton Gutnick Intrauterine contraceptive devices and processes
US4325388A (en) * 1973-02-05 1982-04-20 Louis Bucalo Apparatus for collecting and processing body fluids
US3971376A (en) * 1973-02-26 1976-07-27 Ceskoslovenska Akademie Ved Method and apparatus for introducing fluids into the body
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4111196A (en) * 1973-07-27 1978-09-05 Lionel C. R. Emmett Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
GB1465684A (en) * 1973-07-27 1977-02-23 Emmett L Contraceptive device
US4018220A (en) * 1974-07-19 1977-04-19 Lionel C. R. Emmett Method of insertion for intrauterine device of C or omega form with tubular inserter
US4172446A (en) * 1974-12-20 1979-10-30 Louis Bucalo Apparatus for collecting body fluids
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
AU1147476A (en) * 1975-03-19 1977-09-01 Procter & Gamble Controlled release article
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4073833A (en) * 1975-12-08 1978-02-14 The Procter & Gamble Company Encapsulation process
US4031202A (en) * 1975-12-08 1977-06-21 The Procter & Gamble Company Controlled release contraceptive article
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
SE448203B (sv) * 1980-09-10 1987-02-02 Johan Alfred Olof Johansson formkropp framstelld av agar och/eller agaros och/eller ett derivat derav innehallande farmakologiskt verksamt emne
US4439195A (en) * 1980-10-14 1984-03-27 Alza Corporation Theophylline therapy
US4455145A (en) * 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4552555A (en) * 1981-07-31 1985-11-12 Alza Corporation System for intravenous delivery of a beneficial agent
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
GB2107191B (en) * 1981-07-31 1984-08-30 Alza Corp Parenteral delivery system
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4416659A (en) * 1981-11-09 1983-11-22 Eli Lilly And Company Sustained release capsule for ruminants
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4539004A (en) * 1982-09-22 1985-09-03 Alza Corporation Self-driven pump assembly and method of operation
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4552561A (en) * 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4667032A (en) * 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
US4859667A (en) * 1983-01-21 1989-08-22 Merck Frosst Canada, Inc. Pharmaceutical compositions of phenothiazone derivatives and analogs
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4610686A (en) * 1983-11-02 1986-09-09 Alza Corporation Controlled delivery of haloperidol by an osmotic delivery system
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US5000957A (en) * 1984-03-19 1991-03-19 Alza Corporation Dispenser comprising hydrophilic osmopolymer
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4612186A (en) * 1984-03-19 1986-09-16 Alza Corporation Method for establishing blood levels of biocide in animals
US4624945A (en) * 1984-03-19 1986-11-25 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4844984A (en) * 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4729793A (en) * 1985-08-09 1988-03-08 Alza Corporation Composition for manufacturing wall of dispensing device
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
EP0203186B1 (en) * 1984-12-03 1992-03-04 BAXTER INTERNATIONAL INC. (a Delaware corporation) Drug delivery apparatus preventing local and systemic toxicity
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
JPS61153350U (2) * 1985-03-13 1986-09-22
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
US4717718A (en) * 1985-08-09 1988-01-05 Alza Corporation Device for the controlled delivery of a beneficial agent
US4717568A (en) * 1985-08-09 1988-01-05 Alza Corporation Laminar arrangement for increasing delivery of beneficial agent from dispenser
US4643731A (en) * 1985-08-16 1987-02-17 Alza Corporation Means for providing instant agent from agent dispensing system
US4883667A (en) * 1985-08-16 1989-11-28 Alza Corporation Process for forming dispensing device
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
US4955881A (en) * 1985-08-16 1990-09-11 Alza Corporation Ruminant dispensing device
US4704118A (en) * 1985-08-16 1987-11-03 Alza Corporation Ruminant dispensing device with thermo-activated memory
US5098425A (en) * 1985-08-16 1992-03-24 Alza Corporation Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member
US4963141A (en) * 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4966767A (en) * 1985-08-16 1990-10-30 Alza Corporation Ruminant dispensing device comprising agent displacement member
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4871544A (en) * 1985-08-16 1989-10-03 Alza Corporation Ruminant dispensing device
US4756314A (en) * 1985-10-28 1988-07-12 Alza Corporation Sweat collection patch
US4680266A (en) * 1985-11-21 1987-07-14 Contraves Ag Cell culture chamber with means for automatic replenishment of nutrient
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US4838862A (en) 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
EP0277092B1 (de) * 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutisches System für schwerlösliche Wirkstoffe
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) * 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5023076A (en) * 1987-02-27 1991-06-11 Alza Corporation Lamina comprising carboxyvinyl polymer
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4886668A (en) * 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4950486A (en) * 1987-10-02 1990-08-21 Alza Corporation Dosage form for treating cardiovascular diseases
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5030203A (en) * 1987-11-16 1991-07-09 Baxter International Inc. Ampule for controlled administration of beneficial agent
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5030456A (en) * 1988-11-07 1991-07-09 Alza Corporation Dosage form for treating cardiovascular diseases
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5728088A (en) * 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US4969872A (en) * 1989-03-08 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US20020197309A1 (en) * 1989-09-05 2002-12-26 Kuczynski Anthony L. Method for lowering blood glucose
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5071607A (en) * 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
US5024663A (en) * 1990-02-21 1991-06-18 Alza Corporation Self-contained suction pump
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5147654A (en) * 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
ATE118345T1 (de) * 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5246709A (en) * 1990-09-10 1993-09-21 Alza Corporation Antiemetic therapy
EP0550641B1 (en) * 1990-09-28 1994-05-25 Pfizer Inc. Dispensing device containing a hydrophobic medium
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5861166A (en) * 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5801141A (en) * 1991-06-24 1998-09-01 American Cyanamid Company Implant compositions containing a biologically active protein, peptide or polypeptide
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5254349A (en) * 1991-12-06 1993-10-19 Alza Corporation Process for lessening irritation caused by drug
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
MX9401351A (es) * 1993-02-22 1994-08-31 Alza Corp Composiciones para suministro oral para agentes activos.
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5770076A (en) * 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5798042A (en) * 1994-03-07 1998-08-25 Regents Of The University Of California Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
US5985328A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US5985164A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Method for forming a filter
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5595759A (en) * 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5651979A (en) * 1995-03-30 1997-07-29 Gel Sciences, Inc. Apparatus and method for delivering a biologically active compound into a biological environment
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5690952A (en) * 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US5798119A (en) * 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US5780058A (en) * 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
DE69709646T2 (de) * 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US6024721A (en) 1996-10-18 2000-02-15 Alza Corporation Mixing system for an active agent delivery device
PT936893E (pt) 1996-10-18 2001-12-28 Alza Corp Dispositivo com multiplos percursos de escoamento para a administracao oral de unidades discretas
US6096003A (en) * 1996-10-18 2000-08-01 Alza Corporation Closure system for an active agent delivery device
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
DE69735002T2 (de) * 1996-10-25 2006-10-26 Shire Laboratories, Inc. Osmotisches Verabreichungssystem für lösliche Dosen
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
WO1998039003A1 (en) 1997-03-07 1998-09-11 Cerebrus Limited Use of (+)mefloquine for the treatment of malaria
DK1304105T3 (da) * 1997-03-31 2006-11-20 Alza Corp Implanterbart diffusionsafleveringssystem
WO1998043611A1 (en) * 1997-03-31 1998-10-08 Alza Corporation Diffusional implantable delivery system
PT984762E (pt) 1997-05-16 2002-12-31 Alza Corp Configuracoes de controlador de debito para um dispositivo de administracao de agente activo
US5994148A (en) 1997-06-23 1999-11-30 The Regents Of University Of California Method of predicting and enhancing success of IVF/ET pregnancy
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US6245042B1 (en) 1997-08-27 2001-06-12 Science Incorporated Fluid delivery device with temperature controlled energy source
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
PT1014951E (pt) * 1997-09-09 2005-03-31 Alza Corp Composicao de revestimento farmaceutica e metodo para a sua utilizacao
JP2001517625A (ja) 1997-09-25 2001-10-09 バイエル・アクチエンゲゼルシヤフト 活性成分放出制御薬物製剤
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
DE69805001T2 (de) 1997-12-05 2002-08-22 Alza Corp., Palo Alto Osmotische darreichungsform mit zwei mantelschichten
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO1999033446A1 (en) * 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
AU1937099A (en) 1997-12-31 1999-07-19 Alza Corporation Osmotic drug delivery monitoring system and method
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
AU2349999A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
CO5040088A1 (es) 1998-04-03 2001-05-29 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
TR200103057T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
JP2003522103A (ja) 1998-06-15 2003-07-22 セプラコア インコーポレーテッド 無呼吸、過食症およびその他の障害を治療するための光学的に純粋な（−）−ノルシスアプリドの使用
US6369039B1 (en) * 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US7890176B2 (en) * 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
RU2224523C2 (ru) 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
HK1038508B (en) * 1998-09-09 2006-06-30 Alza Corporation Dosage form comprising liquid formulation
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
IL142807A0 (en) * 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ATE415969T1 (de) 1999-05-07 2008-12-15 Wockhardt Ltd (s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
EP1671628B1 (en) * 1999-09-03 2012-10-03 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6638263B1 (en) 1999-10-12 2003-10-28 Durect Corporation Regulation of drug delivery through flow diversion
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1239840B1 (en) * 1999-12-09 2005-04-06 Alza Corporation Antiviral medication
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US6432446B2 (en) 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1255566A2 (en) * 2000-02-04 2002-11-13 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6616652B1 (en) 2000-02-15 2003-09-09 Microsolutions, Inc. Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
WO2001060348A2 (en) 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6582441B1 (en) 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US6569152B2 (en) * 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
KR20030003708A (ko) * 2000-03-31 2003-01-10 셀진 코포레이션 시클로옥시게나제-2 활성의 저해
WO2001080831A2 (en) 2000-04-27 2001-11-01 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
AU2001296770A1 (en) * 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
BR0115390A (pt) 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
EP1345606A4 (en) * 2000-11-17 2005-02-09 Pharmacyclics Inc TEXAPHYRINE COORDINATION COMPOUNDS AND THEIR USE
US20030195706A1 (en) * 2000-11-20 2003-10-16 Michael Korenberg Method for classifying genetic data
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
JP4248236B2 (ja) 2000-11-29 2009-04-02 デュレクト コーポレイション 薬物送達装置からの送達を制御するための装置および方法
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
US7493172B2 (en) * 2001-01-30 2009-02-17 Boston Scientific Neuromodulation Corp. Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
US20050143789A1 (en) * 2001-01-30 2005-06-30 Whitehurst Todd K. Methods and systems for stimulating a peripheral nerve to treat chronic pain
US20060064140A1 (en) * 2001-01-30 2006-03-23 Whitehurst Todd K Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
IN190699B (2) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US6964966B2 (en) * 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2003003809A2 (en) * 2001-07-05 2003-01-16 Marantech Holding, Llc Methods of using electron active compounds for managing conditions afflicting mammals
DE60223254T2 (de) 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP2005515966A (ja) * 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
EP1283025A1 (de) * 2001-08-10 2003-02-12 Stöckert Instrumente GmbH Ballonokklusionsvorrichtung
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US7157493B2 (en) * 2001-11-28 2007-01-02 Nashai Biotech, Llc Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
CN1630514A (zh) 2001-12-05 2005-06-22 贝勒医学院 通过调节交感神经紧张性控制骨形成的方法和组合物
EP1492509A1 (en) * 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
KR20040066177A (ko) * 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
CA2471081A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US7071335B2 (en) 2002-02-01 2006-07-04 Euro-Celtique S.A. 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
CN1625397A (zh) 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
JP2005527502A (ja) * 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
KR101173497B1 (ko) * 2002-03-11 2012-08-14 알콘, 인코퍼레이티드 이식 가능한 약물 전달 시스템
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP1499289B1 (en) * 2002-03-29 2008-07-23 Alza Corporation Volume efficient controlled release dosage form
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2003092648A1 (en) * 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7458965B2 (en) * 2002-05-01 2008-12-02 Microlin, Llc Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
US20060116663A1 (en) * 2002-05-01 2006-06-01 Joshi Ashok V Electro-osmotic fluid delivery device and method
US7896867B2 (en) * 2002-05-01 2011-03-01 Microlin, Llc Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
US7470267B2 (en) * 2002-05-01 2008-12-30 Microlin, Llc Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CA2752124A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
EP2258363A1 (en) 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
US7151961B1 (en) * 2002-05-24 2006-12-19 Advanced Bionics Corporation Treatment of movement disorders by brain stimulation
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
CA2487786A1 (en) * 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
US6900203B2 (en) 2002-06-19 2005-05-31 Polium Technologies, Inc. Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
KR20050071376A (ko) * 2002-06-28 2005-07-07 알자 코포레이션 액체 활성성분 제제를 포함하고 팽창성 삼투 조성물에의해 그의 방출을 제어하는 경구제형
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
AU2003256755A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US7254449B2 (en) * 2002-07-31 2007-08-07 Advanced Bionics Corp Systems and methods for providing power to one or more implantable devices
DE60335426D1 (de) 2002-08-15 2011-01-27 Euro Celtique Sa Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten
AU2003267756A1 (en) 2002-09-03 2004-03-29 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use
JP2006502158A (ja) 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US20060009739A1 (en) * 2002-09-06 2006-01-12 Durect Corporation Implantable flow regulator with failsafe mode and reserve drug supply
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
AU2003272504A1 (en) 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
PT1543010E (pt) 2002-09-25 2007-07-26 Euro Celtique Sa Hidromorfonas n-substituídas e a sua utilização
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
EP1551386A4 (en) * 2002-09-27 2009-03-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR TREATING LUPUS WITH CLOFARABIN
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
WO2004032864A2 (en) * 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
EP1554270A2 (en) * 2002-10-11 2005-07-20 Proteotech, Inc. Isolation, purification and synthesis of procyanidin b2 and uses thereof
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AR041744A1 (es) * 2002-10-31 2005-05-26 Alza Corp Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida
AU2003291667A1 (en) * 2002-10-31 2004-06-07 Alza Corporation Pharmaceutical formulation providing an increased bioavailability of hydrophobic drugs
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
TW200501945A (en) 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20040111071A1 (en) * 2002-12-09 2004-06-10 Jeffrey Lewis Powers Portable device for dispensing hand treatments
US8286834B2 (en) * 2002-12-09 2012-10-16 Jeffrey Lewis Powers Skin treatment dispenser and method of manufacture
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CA2508948A1 (en) * 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006522016A (ja) * 2003-01-14 2006-09-28 アルザ・コーポレーシヨン 改変された粘度の層を用いる方法および投薬形態物
KR20050092424A (ko) 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
ATE550022T1 (de) 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
HUE047569T2 (hu) 2003-04-11 2020-04-28 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20070083240A1 (en) * 2003-05-08 2007-04-12 Peterson David K L Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
WO2005000786A1 (en) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US7141696B2 (en) * 2003-05-23 2006-11-28 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
JP2007516234A (ja) * 2003-05-27 2007-06-21 アテニュオン，リミティド ライアビリティー カンパニー チオタングステン酸（塩）アナログ及びその使用
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
CA2529852A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
US20050009782A1 (en) * 2003-07-09 2005-01-13 Comper Wayne D. Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
TWI376370B (en) * 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
GEP20094676B (en) * 2003-07-24 2009-05-10 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
DE602004017316D1 (de) 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
CN1859897A (zh) * 2003-07-31 2006-11-08 阿尔扎公司 用于液态活性剂制剂控制释放的抗渗透的渗透装置和剂型
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005012287A1 (en) * 2003-08-01 2005-02-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
BRPI0413756A (pt) * 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2005023181A2 (en) * 2003-08-22 2005-03-17 Vista Scientific Polymeric systems for controlled drug therapy
MXPA06002067A (es) * 2003-08-22 2006-08-11 Johnson & Johnson Suministro gradual de topiramato durante periodo prolongado.
GB0320020D0 (en) 2003-08-27 2003-10-01 Mw Encap Ltd Improved formulation for providing an enteric coating material
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP5255183B2 (ja) * 2003-09-04 2013-08-07 ウォックハート リミテッド ベンゾキノリジン−２−カルボン酸アルギニン塩四水和物
US7230003B2 (en) * 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
NZ579515A (en) * 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
SI1664016T1 (sl) * 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
EP1663229B1 (en) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
WO2005030165A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Dosage form for controlled release of an active agent formulation
MXPA06003451A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formas de dosificacion osmotica para suministro controlado de alprazolam.
CN102697704A (zh) * 2003-09-26 2012-10-03 阿尔扎公司 阿片类与非阿片类镇痛药的控释制剂
NZ546183A (en) 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
US20050186273A1 (en) * 2003-09-26 2005-08-25 Si-Hong Yum Controlled release dosage form including a banded engine
MXPA06003453A (es) 2003-09-26 2006-08-31 Johnson & Johnson Barra de empuje oros para el suministro controlado de agentes activos.
CA2540308C (en) 2003-09-26 2013-08-06 Alza Corporation Drug coating providing high drug loading and methods for providing the same
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20050118246A1 (en) * 2003-10-31 2005-06-02 Wong Patrick S. Dosage forms and layered deposition processes for fabricating dosage forms
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
KR20060124607A (ko) * 2003-11-06 2006-12-05 셀진 코포레이션 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AU2004291081A1 (en) * 2003-11-14 2005-06-02 Alza Corporation Controlled release of topirimate in liquid dosage forms
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
CA2547137A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP5122821B2 (ja) 2003-11-28 2013-01-16 イーストマン ケミカル カンパニー セルロースインターポリマー及び酸化方法
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005062829A2 (en) * 2003-12-19 2005-07-14 Advanced Bionics Corporation Skull-mounted electrical stimulation system and method for treating patients
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
EP1701706A2 (en) * 2003-12-29 2006-09-20 Alza Corporation Novel drug compositions and dosage forms
BRPI0418212A (pt) * 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
RU2374244C2 (ru) 2004-01-07 2009-11-27 Арикс Терапьютикс Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
CA2556220A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
PT1720540E (pt) 2004-02-18 2008-09-10 Gpc Biotech Ag Métodos de tratamento de tumores resistentes ou refractários
WO2005082382A1 (en) * 2004-02-23 2005-09-09 Attenuon Llc Formulations of thiomolybdate or thiotungstate compounds and uses thereof
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US7612071B2 (en) 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
CA2560221C (en) 2004-03-22 2010-12-07 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
WO2005092065A2 (en) * 2004-03-25 2005-10-06 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
ATE413398T1 (de) * 2004-04-08 2008-11-15 Wyeth Corp Thioamidderivate als progesteronrezeptormodulatoren
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
AU2004319758A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
EP1756072A2 (en) 2004-04-27 2007-02-28 Wyeth Purification of progesterone receptor modulators
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US20050267555A1 (en) * 2004-05-28 2005-12-01 Marnfeldt Goran N Engagement tool for implantable medical devices
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
CA2568249C (en) * 2004-05-28 2014-12-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
EP1755388B1 (en) 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
EP1771435A4 (en) * 2004-06-19 2008-02-13 Human Biomolecular Res Inst MODULATORS OF NEUROTRANSMITTERS OF THE CENTRAL NERVOUS SYSTEM
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
EP1761265A2 (en) * 2004-06-28 2007-03-14 ALZA Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20080027513A1 (en) * 2004-07-09 2008-01-31 Advanced Bionics Corporation Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
US7241807B2 (en) * 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
DE602005010270D1 (de) * 2004-07-12 2008-11-20 Xenoport Inc Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
JP2008509154A (ja) * 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
NZ552390A (en) * 2004-08-06 2010-01-29 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
CN101022788B (zh) * 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru) * 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
US8452407B2 (en) * 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
DE602005019582D1 (de) * 2004-08-30 2010-04-08 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
JP5132310B2 (ja) * 2004-09-08 2013-01-30 スパイナル・モデュレーション・インコーポレイテッド 神経刺激の方法及びシステム
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
CA2580767A1 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR20070084211A (ko) 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
EP1799221A1 (en) 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
KR20070083714A (ko) * 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
US20090170790A1 (en) * 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
RU2398773C2 (ru) 2004-11-02 2010-09-10 Баниу Фармасьютикал Ко., Лтд. Арилоксизамещенное производное бензимидазола
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
MX2007005306A (es) * 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US9358393B1 (en) 2004-11-09 2016-06-07 Andres M. Lozano Stimulation methods and systems for treating an auditory dysfunction
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US7483746B2 (en) * 2004-12-06 2009-01-27 Boston Scientific Neuromodulation Corp. Stimulation of the stomach in response to sensed parameters to treat obesity
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
WO2006065793A2 (en) 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
US7560544B2 (en) 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
US20070038264A1 (en) * 2004-12-21 2007-02-15 Jaax Kristen N Methods and systems for treating autism
US9327069B2 (en) 2004-12-21 2016-05-03 Boston Scientific Neuromodulation Corporation Methods and systems for treating a medical condition by promoting neural remodeling within the brain
US20060161217A1 (en) * 2004-12-21 2006-07-20 Jaax Kristen N Methods and systems for treating obesity
US9095713B2 (en) * 2004-12-21 2015-08-04 Allison M. Foster Methods and systems for treating autism by decreasing neural activity within the brain
US9352145B2 (en) * 2004-12-22 2016-05-31 Boston Scientific Neuromodulation Corporation Methods and systems for treating a psychotic disorder
US8515541B1 (en) 2004-12-22 2013-08-20 Boston Scientific Neuromodulation Corporation Methods and systems for treating post-stroke disorders
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
EP1844000B1 (en) * 2004-12-23 2010-01-27 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
KR20140018997A (ko) * 2005-01-07 2014-02-13 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
PL1848435T3 (pl) 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
ATE413864T1 (de) * 2005-01-27 2008-11-15 Alza Corp Orale osmotische darreichungsform mit membran mit hoher flussdichte
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1690540A1 (en) 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
US20060185665A1 (en) * 2005-02-22 2006-08-24 Bachinski Thomas J Sauna fireplace
US20060194724A1 (en) * 2005-02-25 2006-08-31 Whitehurst Todd K Methods and systems for nerve regeneration
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US7312217B2 (en) 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
US7702385B2 (en) * 2005-11-16 2010-04-20 Boston Scientific Neuromodulation Corporation Electrode contact configurations for an implantable stimulator
US7848803B1 (en) 2005-03-14 2010-12-07 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US8423155B1 (en) 2005-03-14 2013-04-16 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US20060206165A1 (en) * 2005-03-14 2006-09-14 Jaax Kristen N Occipital nerve stimulation to treat headaches and other conditions
US7853321B2 (en) 2005-03-14 2010-12-14 Boston Scientific Neuromodulation Corporation Stimulation of a stimulation site within the neck or head
EP1865954A4 (en) 2005-03-21 2010-12-15 Metabolex Inc METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER
ATE534652T1 (de) 2005-04-01 2011-12-15 Univ California Phosphono-pent-2-en-1-yl-nukleoside und analoga
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
ES2545589T3 (es) 2005-04-08 2015-09-14 Abbott Laboratories Formulaciones farmacéuticas orales que comprenden sales de ácido fenofíbrico
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
EP1874782A1 (en) * 2005-04-15 2008-01-09 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006242154B2 (en) 2005-05-02 2011-11-03 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
ZA200711123B (en) * 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US7423045B2 (en) * 2005-06-28 2008-09-09 Cv Therapeutics, Inc. ABCA1 elevating compounds
KR20080030637A (ko) * 2005-06-29 2008-04-04 알자 코포레이션 삼투성 제형에 대하여 감소된 건조 시간을 제공하는반투과성 조성물
US8348930B2 (en) * 2005-07-01 2013-01-08 Microlin, Llc Fluid delivery device with a diffusion membrane and electrochemical pump
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US20070009573A1 (en) * 2005-07-07 2007-01-11 L N K International Method of forming immediate release dosage form
TWI279234B (en) * 2005-07-12 2007-04-21 Anchen Pharmaceuticals Taiwan Method for controlling lag time of in-situ passageway formation in osmotic delivery system
US20070025869A1 (en) * 2005-07-15 2007-02-01 Gordon John H Fluid Delivery Device
US20070021734A1 (en) * 2005-07-15 2007-01-25 Sai Bhavaraju Bioelectro-osmotic engine fluid delivery device
US20070023291A1 (en) * 2005-07-15 2007-02-01 Sai Bhavaraju Metal Trap
JP2009505955A (ja) 2005-07-22 2009-02-12 アムゲン インコーポレイティッド アニリンスルホンアミド誘導体およびそれらの使用
JP2009507774A (ja) * 2005-08-04 2009-02-26 アルザ・コーポレーシヨン 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
WO2007031887A2 (en) * 2005-08-30 2007-03-22 Nicholas Piramal India Limited Extended release pharmaceutical composition of metformin and a process for producing it
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
AU2006284601B2 (en) 2005-08-31 2012-12-20 Renexxion, Llc Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US7684858B2 (en) * 2005-09-21 2010-03-23 Boston Scientific Neuromodulation Corporation Methods and systems for placing an implanted stimulator for stimulating tissue
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
ATE497960T1 (de) * 2005-10-13 2011-02-15 Cv Therapeutics Inc A1-adenosinrezeptoragonisten
US20070092585A1 (en) * 2005-10-14 2007-04-26 Skinner Michael K Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
MX2008006037A (es) 2005-11-10 2009-03-03 Circ Pharma Res And Dev Ltd Drogas para el sistema nervioso central para administracion una-vez-al-dia.
CN101356189A (zh) * 2005-11-10 2009-01-28 受体生物公司 肝细胞生长因子内含子融合蛋白
CN101563097A (zh) 2005-11-14 2009-10-21 企业合伙人风险资本公司 用于组织损伤的干细胞生长因子疗法
PT1951718E (pt) 2005-11-21 2012-05-21 Purdue Pharma Lp Compostos de 4-oxadiazolil-piperidina e as suas utilizações
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7982066B2 (en) * 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US7835803B1 (en) * 2006-01-17 2010-11-16 Boston Scientific Neuromodulation Corporation Lead assemblies with one or more switching networks
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
US8455658B2 (en) * 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US7816535B2 (en) 2006-01-25 2010-10-19 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070254926A1 (en) 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
US20070196487A1 (en) * 2006-02-16 2007-08-23 Geerke Johan H Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20070201024A1 (en) * 2006-02-28 2007-08-30 Geerke Johan H Method and apparatus for semi-permeable membrane detection on osmotic tablets incorating near-infrared spectroscopy
AU2007225273A1 (en) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
CA2645376C (en) 2006-03-13 2017-06-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
US8175710B2 (en) * 2006-03-14 2012-05-08 Boston Scientific Neuromodulation Corporation Stimulator system with electrode array and the method of making the same
US20070219174A1 (en) * 2006-03-15 2007-09-20 Pharmacyclics, Inc. Methods of treating cancer using hypofractionated radiation and texaphyrins
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
JP2009535552A (ja) * 2006-04-28 2009-10-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 少なくとも１つの帯電可能な材料を有する浸透圧ポンプ
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
MX2008014794A (es) 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
ATE476418T1 (de) * 2006-06-08 2010-08-15 Amgen Inc Benzamidderivate und assoziierte verwendungen
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
JP2009539412A (ja) * 2006-06-12 2009-11-19 レセプター バイオロジックス， インコーポレイテッド 汎細胞表面レセプター特異的な治療薬
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
NZ573875A (en) 2006-06-22 2011-11-25 Anadys Pharmaceuticals Inc Pyrro[1,2-b]pyridazinone compounds
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8401654B1 (en) 2006-06-30 2013-03-19 Boston Scientific Neuromodulation Corporation Methods and systems for treating one or more effects of deafferentation
US8504163B1 (en) 2006-06-30 2013-08-06 Boston Scientific Neuromodulation Corporation Cranially mounted stimulation systems and methods
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
KR20090033417A (ko) 2006-07-27 2009-04-03 씨브이 쎄러퓨틱스, 인코포레이티드 중독의 치료에서의 ａｌｄｈ-2 저해제
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
MX2009000923A (es) * 2006-08-04 2009-03-09 Agi Therapeutics Res Ltd Metodos para tratar cuando menos una condicion que tiene receptor de mt1, receptor de 5ht2b, y actividad de canal de calcio tipo l.
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
US7445528B1 (en) 2006-09-29 2008-11-04 Boston Scientific Neuromodulation Corporation Connector assemblies
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2665476A1 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
AU2007307635A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP2617423A1 (en) 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US7347746B1 (en) 2006-10-27 2008-03-25 Boston Scientific Neuromodulation Corporation Receptacle connector assembly
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
US20080207641A1 (en) 2006-11-13 2008-08-28 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
EP2591675A1 (en) 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008070529A2 (en) 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
WO2008070808A2 (en) * 2006-12-06 2008-06-12 Spinal Modulation, Inc. Expandable stimulation leads and methods of use
WO2008070809A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
AU2007329253B2 (en) 2006-12-06 2014-03-27 Spinal Modulation, Inc. Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
CA2671250A1 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Hard tissue anchors and delivery devices
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
AU2007333586A1 (en) 2006-12-11 2008-06-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
US20080147186A1 (en) * 2006-12-14 2008-06-19 Joshi Ashok V Electrochemical Implant For Delivering Beneficial Agents
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US20080188528A1 (en) * 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
CA2673586A1 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
EP2397477B1 (en) * 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclic-substituted piperidine compounds and the uses thereof
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
AU2008210504B2 (en) * 2007-01-29 2012-07-26 Spinal Modulation, Inc. Sutureless lead retention features
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
NZ599480A (en) 2007-02-21 2013-10-25 Sunovion Pharmaceuticals Inc Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
AR065628A1 (es) * 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
EP2137150A1 (en) * 2007-03-12 2009-12-30 Biolipox AB Piperidinones useful in the treatment of inflammation
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
CA2681560A1 (en) * 2007-04-09 2008-10-16 Cv Therapeutics, Inc. Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2685118C (en) 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
MX2009011601A (es) 2007-04-27 2009-11-10 Purdue Pharma Lp Agentes terapeuticos utiles para tratar el dolor.
CA2685266C (en) * 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
EP2019101A1 (en) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
AU2008259841B2 (en) 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US8415294B2 (en) * 2007-06-05 2013-04-09 Arizona Board Of Regents Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
WO2008151288A2 (en) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) * 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US20080306076A1 (en) * 2007-06-08 2008-12-11 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
CN101730467A (zh) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 神经病性疼痛的治疗
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009017831A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
CA2695143A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
HUE034563T2 (en) 2007-08-10 2018-02-28 Vm Discovery Inc Preparations and methods comprising apotheque modulators
CN101821276B (zh) 2007-08-13 2016-08-31 症变治疗公司 新颖的葡糖激酶活化剂
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
MY150602A (en) 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
CN102351880B (zh) * 2007-09-11 2014-11-12 杏林制药株式会社 作为gsk-3 抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
CZ300468B6 (cs) * 2007-09-20 2009-05-27 Zentiva, A. S Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
CA2704710C (en) 2007-09-26 2016-02-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
AR068540A1 (es) * 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS
JP5301456B2 (ja) 2007-11-12 2013-09-25 Ｍｓｄ株式会社 ヘテロアリールオキシキナゾリン誘導体
RS55769B1 (sr) 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090162417A1 (en) * 2007-12-21 2009-06-25 Cook Incorporated Drug eluting ocular conformer
WO2009081782A1 (ja) 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. Ｎ－ピラゾール－２－ピリジンカルボキサミド誘導体
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US20090203689A1 (en) * 2008-02-07 2009-08-13 Arvinder Dhalla Abca-1 elevating compounds and methods
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP3147281A1 (en) 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
MX2010010272A (es) 2008-03-19 2011-05-25 Chembridge Corp Nuevos inhibidores de tirosina quinasa.
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2276483B1 (en) 2008-03-27 2014-05-07 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
AU2009231906A1 (en) * 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
KR101715631B1 (ko) 2008-04-01 2017-03-13 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
BRPI0910987A2 (pt) * 2008-04-04 2017-03-21 Gilead Sciences Inc derivados de triazolopiridinona para uso como inibidores de estearoil-coa dessaturase
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
CN102083466A (zh) * 2008-05-20 2011-06-01 科莱尼斯医疗公司 用于组合疗法的烟酸和nsaid
EP2299814A4 (en) * 2008-05-27 2011-06-15 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR USE OF ANTIPSYCHOTICS ON PIPERAZINE BASIS
CA2725316A1 (en) 2008-06-02 2009-12-10 Banyu Pharmaceutical Co., Ltd. Novel isoxazole derivative
US8894602B2 (en) 2010-09-17 2014-11-25 Johnson & Johnson Vision Care, Inc. Punctal plugs with directional release
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
TW201004632A (en) 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
KR101333660B1 (ko) 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도
EP2299983A4 (en) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
ES2449222T3 (es) 2008-07-30 2014-03-18 Purdue Pharma Lp Análogos de buprenorfina
WO2010014813A2 (en) 2008-07-31 2010-02-04 Senomyx, Inc. Compositions comrpising sweetness enhancers and methods of making them
ES2915065T3 (es) 2008-07-31 2022-06-20 Firmenich Incorporated Procedimientos para hacer potenciadores del sabor dulce
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
AU2009300317A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
US20110229438A1 (en) 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
WO2010042925A2 (en) 2008-10-10 2010-04-15 Vm Discovery Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
JP5643764B2 (ja) 2008-10-27 2014-12-17 スパイナル・モデュレーション・インコーポレイテッドＳｐｉｎａｌ Ｍｏｄｕｌａｔｉｏｎ Ｉｎｃ． 選択的刺激システムおよび医学的状態の信号パラメータ
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
RU2673882C1 (ru) 2008-10-30 2018-12-03 Грюненталь Гмбх Новые и эффективные лекарственные формы тапентадола
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US8389500B2 (en) 2008-10-30 2013-03-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
RU2484827C2 (ru) 2008-11-04 2013-06-20 Юниверсити Оф Кентукки Рисерч Фаундэйшн Композиции на основе d-тагатозы и способы предупреждения и лечения атеросклероза, метаболического синдрома и их симптомов
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
CN105384676B (zh) 2008-12-16 2019-05-07 桑诺维恩药品公司 三重再摄取抑制剂及其应用方法
EP2376633A1 (en) 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2379504A2 (en) 2008-12-22 2011-10-26 Sloan Kettering Institute For Cancer Research Coumarin-based compounds
JP2012513468A (ja) 2008-12-22 2012-06-14 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 癌及び神経変性疾患の治療又は予防方法
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
EP2393491B1 (en) 2009-02-03 2020-04-22 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
CN102340992B (zh) 2009-02-09 2014-11-05 桑诺维恩药品公司 吡咯烷三重再摄取抑制剂
EP2395995A1 (en) 2009-02-10 2011-12-21 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
BRPI1008020A2 (pt) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
AU2010216633A1 (en) 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
NZ595263A (en) * 2009-02-26 2013-06-28 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
MY159327A (en) 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
EP2403523A1 (en) * 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2406248B1 (en) 2009-03-11 2013-12-25 Msd K.K. Novel isoindolin-1-one derivative
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
JP2012521801A (ja) 2009-03-24 2012-09-20 スパイナル・モデュレーション・インコーポレイテッド 錯感覚に対する閾値以下の刺激を伴う疼痛の管理
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
MX2011011080A (es) 2009-04-22 2012-02-23 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
ES2556235T3 (es) 2009-04-22 2016-01-14 Axikin Pharmaceuticals, Inc. Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
RU2539591C2 (ru) 2009-04-22 2015-01-20 Аксикин Фармасьютикалз, Инк. Антагонисты арилсульфонамида ccr3
US8809382B2 (en) 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2010132816A2 (en) 2009-05-15 2010-11-18 Spinal Modulation, Inc. Methods, systems and devices for neuromodulating spinal anatomy
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
US8956654B2 (en) 2009-06-02 2015-02-17 Dow Global Technologies Llc Sustained release dosage form
SG176735A1 (en) 2009-06-10 2012-01-30 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
AU2010270605B2 (en) 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
ES2642586T3 (es) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
WO2011019752A2 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
JP2013503908A (ja) 2009-09-04 2013-02-04 ユナイテッド パラゴン アソシエイツ インコーポレイテッド ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
MX2012002898A (es) 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
WO2011042482A1 (en) 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
US20110082198A1 (en) * 2009-10-07 2011-04-07 Jiangsu Dehe Bio-Tech Co., Ltd. Theaflavin compositions, production, and methods to control physiological disorders in mammals
US8282970B2 (en) * 2009-10-07 2012-10-09 Jiahgsu Dehe Bio-Tech Co., Ltd Theaflavin compositions, related processes and methods of use
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
EP2490688B1 (en) 2009-10-19 2014-10-08 Synta Pharmaceuticals Corp. Combination cancer therapy with hsp90 inhibitory compounds
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US20140004182A1 (en) 2009-11-19 2014-01-02 Jerome B. Zeldis Methods for the treatment of sarcoidosis
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
NZ600107A (en) 2009-12-04 2014-10-31 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and uses thereof
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
BR112012015129A2 (pt) 2009-12-22 2019-09-24 Celgene Corp "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
IN2012DN04858A (2) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX337566B (es) 2010-01-05 2016-03-10 Celgene Corp Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011091164A1 (en) * 2010-01-22 2011-07-28 Xenoport, Inc. Oral dosage forms having a high loading of a tranexamic acid prodrug
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EA027622B1 (ru) 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Твердофазные формы макроциклических ингибиторов киназы
US8471041B2 (en) * 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2542542B1 (en) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
KR20130038838A (ko) 2010-03-12 2013-04-18 셀진 코포레이션 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
TW201134820A (en) 2010-03-17 2011-10-16 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
CN103079558B (zh) 2010-04-05 2025-09-12 上海复星医药产业发展有限公司 IRE-1α抑制剂
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
EP2556082B1 (en) 2010-04-08 2017-02-22 Emory University Substituted androst-4-ene diones
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2560641A2 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CN103079489B (zh) 2010-05-10 2016-11-16 脊髓调制公司 用于减少迁移的方法、系统和装置
WO2011146803A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
EP2575810A1 (en) 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
JP2013528180A (ja) 2010-05-28 2013-07-08 ジーイー・ヘルスケア・リミテッド 放射性標識化合物及びその製造方法
EP2576513A1 (en) 2010-06-01 2013-04-10 Biotheryx Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
AU2011261501B2 (en) 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス, エルエルシーNovomedix, Llc フラニル化合物およびその使用
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
JP5847813B2 (ja) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
US20120003329A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
NZ604831A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
WO2012007159A2 (en) 2010-07-14 2012-01-19 Grünenthal GmbH Novel gastro-retentive dosage forms
WO2012012370A1 (en) 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
WO2012021837A2 (en) 2010-08-12 2012-02-16 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
JP5820476B2 (ja) 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーＡＬＧＩＡＸ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＧｍｂＨ レフルノミドおよびマロノニトリラマイドの新規の使用
JP2013540464A (ja) 2010-08-30 2013-11-07 サイナシス コーポレーション 副鼻腔開口部を拡張するため、および副鼻腔炎を治療するためのデバイスおよび方法
EP2611793A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US20130225614A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
AU2011296046B2 (en) 2010-09-01 2015-05-14 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
AU2011296078B2 (en) 2010-09-01 2015-06-18 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
EP2663553B1 (en) 2010-09-01 2015-08-26 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
CN103269701A (zh) 2010-09-13 2013-08-28 辛塔医药品有限公司 用于治疗野生型egfr和/或kras患者的非小细胞肺癌的hsp90抑制剂
WO2012037155A2 (en) 2010-09-13 2012-03-22 Gtx, Inc. Tyrosine kinase inhibitors
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
SG189019A1 (en) 2010-10-18 2013-05-31 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
MX2013004364A (es) 2010-10-19 2013-07-02 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
PT2632451T (pt) 2010-10-29 2017-12-14 Algiax Pharmaceuticals Gmbh Utilização de malononitrilamidas na dor neuropática
EP2638032A1 (en) 2010-11-09 2013-09-18 Synta Pharmaceuticals Corp. Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2640359A4 (en) 2010-11-18 2015-11-04 Gen Hospital Corp NOVEL COMPOSITIONS AND USES OF HYPOTENSE AGENTS IN THE TREATMENT OF CANCER
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
US20140005145A1 (en) 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US20120157938A1 (en) 2010-12-16 2012-06-21 Tokarski Jason M Punctal plug with drug core retention features
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
JP6143675B2 (ja) 2010-12-16 2017-06-07 セルジーン コーポレイション 難溶性薬物の制御放出経口剤形及びその使用
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2661266B1 (en) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
EP2663549B1 (en) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
JP2014505054A (ja) 2011-01-10 2014-02-27 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの経口剤形
US20130331357A1 (en) 2011-01-11 2013-12-12 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
EP2670478B1 (en) 2011-02-02 2016-07-27 Spinal Modulation Inc. Devices and systemsfor the targeted treatment of movement disorders
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012116061A1 (en) 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
AU2012243289A1 (en) 2011-02-24 2013-08-29 Synta Pharmaceuticals Corp. Prostate cancer therapy with Hsp90 inhibitory compounds
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
PH12013501837A1 (en) 2011-03-11 2013-11-18 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
EP2685983B1 (en) 2011-03-17 2016-05-18 Algiax Pharmaceuticals GmbH Novel use of imidazotriazinones
US20140057978A1 (en) 2011-03-17 2014-02-27 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US20120321590A1 (en) 2011-04-06 2012-12-20 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
JP6022548B2 (ja) 2011-04-28 2016-11-09 セルジーン コーポレイション Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CA2834928C (en) 2011-05-03 2017-10-17 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US9301874B2 (en) 2011-05-06 2016-04-05 Johnson & Johnson Vision Care, Inc. Punctal plugs for controlled release of therapeutic agents
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
MY183704A (en) 2011-06-07 2021-03-09 Anadys Pharmaceuticals Inc [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
WO2012175698A1 (en) 2011-06-23 2012-12-27 Université Libre de Bruxelles Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
NO3175985T3 (2) 2011-07-01 2018-04-28
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
DE102011051653A1 (de) * 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
US20140296176A1 (en) 2011-08-19 2014-10-02 Synta Pharmaceuticals Corp. Combination cancer therapy with an hsp90 inhibitor and an antimetabolite
CA2844775A1 (en) 2011-08-23 2013-02-28 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
TWI468403B (zh) 2011-08-30 2015-01-11 Gilead Sciences Inc 用於治療成癮之ａｌｄｈ－２抑制劑
WO2013033636A2 (en) 2011-09-01 2013-03-07 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
CA2849708A1 (en) 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
CA2849903A1 (en) 2011-09-26 2013-04-04 Celgene Corporation Combination therapy for chemoresistant cancers
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US9139519B2 (en) 2011-10-07 2015-09-22 Epicentrx, Inc. Organonitro thioether compounds and medical uses thereof
WO2013052776A1 (en) 2011-10-07 2013-04-11 Cedars-Sinai Medical Center Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US20140271657A1 (en) 2011-10-12 2014-09-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
AU2012322095B2 (en) 2011-10-14 2017-06-29 Ambit Biosciences Corporation Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
BR112014013649A2 (pt) 2011-12-06 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University métodos e agentes para o tratamento de doenças virais e usos dos referidos agentes
EP2788358B1 (en) 2011-12-08 2018-08-29 Purdue Pharma LP Quaternized buprenorphine analogs
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US20130172342A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
EP2797916B1 (en) 2011-12-28 2017-02-15 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
EP2809656A2 (en) 2011-12-28 2014-12-10 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
SG11201403746SA (en) 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2013119895A1 (en) 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013126394A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
TWI635855B (zh) 2012-02-29 2018-09-21 壯生和壯生視覺關懷公司 具有激能圍阻陣列之淚管塞
EP2819740A4 (en) 2012-02-29 2015-11-25 Sinusys Corp DEVICES AND METHOD FOR DILATING A PARANASAL SINUS OPENING AND FOR TREATING SINUSITIS
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
EP2828289B1 (en) 2012-03-19 2020-02-26 The Brigham and Women's Hospital, Inc. Growth differentiation factor (gdf) 11 for treatment of age-related cardiovascular condition
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US9169207B2 (en) 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
WO2013148857A1 (en) 2012-03-28 2013-10-03 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
CA2868323A1 (en) 2012-04-04 2013-10-10 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AU2013255050B2 (en) 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
AR091027A1 (es) 2012-05-11 2014-12-30 Purdue Pharma Lp Analogos de benzomorfano y el usos de estos
US9074972B2 (en) 2012-05-16 2015-07-07 Dionex Corporation Surrogate addition device and a method of analyte concentration
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
EP2861256B1 (en) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014014427A1 (en) 2012-07-16 2014-01-23 Mahmut Bilgic Modified release pharmaceutical tablet formulations
EP2872516B1 (en) 2012-07-16 2017-08-30 Rhodes Technologies Process for improved opioid synthesis
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
BR112015002380B1 (pt) 2012-08-06 2021-09-28 Firmenich Incorporated Composto, composições ingeríveis, processos para aumentar o sabor doce de composição e formulação flavorizante concentrada
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
AU2013299627C1 (en) 2012-08-09 2018-05-31 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
LT2882441T (lt) 2012-08-09 2020-07-27 Celgene Corporation Su imunitetu susijusių ir uždegiminių ligų gydymas
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
WO2014039748A1 (en) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
EP2892537A1 (en) 2012-09-10 2015-07-15 Celgene Corporation Methods for the treatment of locally advanced breast cancer
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
HK1213788A1 (zh) 2012-10-12 2016-07-15 布里格姆及妇女医院股份有限公司 免疫應答的增强
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
JP2015536991A (ja) 2012-11-09 2015-12-24 セルジーン コーポレイション 骨量の減少の治療方法
EP2917182B1 (en) 2012-11-09 2018-01-03 Purdue Pharma LP Benzomorphan analogs and the use thereof
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2938624A1 (en) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
AU2013352463B2 (en) 2012-11-29 2017-06-15 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
WO2014085633A1 (en) 2012-11-30 2014-06-05 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
ES2623262T3 (es) 2012-12-14 2017-07-10 Purdue Pharma Lp Derivados de morfinano que contienen nitrógeno y el uso de los mismos
EP2931724B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonemorphinan analogs and biological activity on opioid receptors
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
US8946255B2 (en) 2012-12-28 2015-02-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
WO2014106238A1 (en) 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
CN105101956B (zh) 2013-01-05 2018-12-07 埃尔舍利克斯治疗公司 包含双胍的延迟释放组合物
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
WO2014110127A1 (en) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
AU2014205356A1 (en) 2013-01-09 2015-07-30 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151180A1 (en) 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2970434B1 (en) 2013-03-15 2018-12-05 The Regents of The University of California Dual reactivity potent kunitz inhibitor of fibrinolysis
SG10201800188SA (en) 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
BR112015025252A2 (pt) 2013-04-02 2017-07-18 Celgene Corp métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
ES2924479T3 (es) 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9687263B2 (en) 2013-05-30 2017-06-27 SinuSys Corporation Devices and methods for inserting a sinus dilator
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3004396B1 (en) 2013-06-06 2019-10-16 The General Hospital Corporation Compositions for the treatment of cancer
US20160220640A1 (en) 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
AU2014278011B2 (en) 2013-06-14 2020-03-19 Alyssum Therapeutics, Inc. Lipid-based platinum compounds and nanoparticles
PL3008053T3 (pl) 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2014210596A1 (en) 2013-06-28 2014-12-31 Purdue Pharma L.P. Treating an arrhythmia with an opioid antagonist
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015009534A2 (en) 2013-07-16 2015-01-22 Allergan, Inc. Hcn inhibitors affecting ganglion cell function and visual function
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20160213659A1 (en) 2013-09-24 2016-07-28 George Sylvestre Treatment of burn pain by trpv1 modulators
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3683321B1 (en) 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en) 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015081073A2 (en) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
EP3074389B1 (en) 2013-11-26 2019-08-14 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR20160090903A (ko) 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
ES2912283T3 (es) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
NZ720651A (en) 2013-12-19 2017-12-22 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN111729090A (zh) 2013-12-20 2020-10-02 通用医疗公司 与循环肿瘤细胞相关的方法和测定法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
EP3094633B1 (en) 2014-01-15 2018-03-14 Rhodes Technologies Process for improved oxymorphone synthesis
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
KR101723997B1 (ko) 2014-02-05 2017-04-06 브이엠 온콜로지 엘엘씨 화합물의 조성물 및 이의 용도
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CA2942313C (en) 2014-03-10 2023-02-07 Kadmon Corporation, Llc Treatment of brain and central nervous system tumors
AU2015233686B2 (en) 2014-03-18 2019-07-11 Algiax Pharmaceuticals Gmbh 2-Cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
JP6568926B2 (ja) 2014-03-20 2019-08-28 カペラ セラピューティクス，インコーポレーテッド 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
WO2015153153A1 (en) 2014-04-02 2015-10-08 Gilead Sciences, Inc. Methods of treating patients having implantable cardiac devices
BR112016022499A2 (pt) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2015164605A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
EP3134041A1 (en) 2014-04-25 2017-03-01 Johnson & Johnson Vision Care Inc. Method and ophthalmic device with active agent release system
AU2015249946A1 (en) 2014-04-25 2016-11-17 The Brigham And Women's Hospital Inc. Methods to manipulate alpha-fetoprotein (AFP)
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3139924A4 (en) 2014-05-06 2018-03-07 Anthony G. Visco Methods of treating or preventing preterm labor
JP2017515854A (ja) 2014-05-12 2017-06-15 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤による慢性肝疾患の合併症の治療
ES2751773T3 (es) 2014-05-15 2020-04-01 Amgen Europe Gmbh Uso de inhibidores pde4 y combinaciones de los mismos para el tratamiento de la fibrosis quística
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
BR112016027096B1 (pt) 2014-05-19 2023-04-11 Northeastern University Composições farmacêuticas e compostos de receptores-alvo de serotonina e seus usos
EP3145500A1 (en) 2014-05-23 2017-03-29 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
AU2015274637B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3174550B1 (en) 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
CN107106704A (zh) 2014-08-29 2017-08-29 儿童医疗中心有限公司 用于治疗癌症的方法和组合物
EP3777863A1 (en) 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
MY198587A (en) 2014-09-14 2023-09-06 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
CN111808136B (zh) 2014-09-15 2024-06-11 加利福尼亚大学董事会 核苷酸类似物
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
UA119794C2 (uk) 2014-10-21 2019-08-12 Аріад Фармасьютикалз, Інк. Кристалічна форма 5-хлор-n4-[2-(диметилфосфорил)феніл]-n2-{2-метокси-4-[4-(4-метилпіперазин-1-іл)піперидин-1-іл]}піримідин-2,4-діаміну
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CA2970358A1 (en) 2014-12-16 2016-06-23 Celgene Corporation Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
TWI703133B (zh) 2014-12-23 2020-09-01 美商艾克斯基製藥公司 ３,５-二胺基吡唑激酶抑制劑
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
CN107249592A (zh) 2015-01-12 2017-10-13 雷维瓦药品公司 用于治疗阿尔茨海默病的方法
WO2016115039A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating pulmonary hypertension
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
HK1244436A1 (zh) 2015-02-09 2018-08-10 Synta Pharmaceuticals Corp. 治疗癌症的hsp90抑制剂和pd-1抑制剂的组合疗法
EP3258914A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist
US20180104251A1 (en) 2015-03-09 2018-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of glioblastoma
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
US12551526B2 (en) 2015-04-22 2026-02-17 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US10815264B2 (en) 2015-05-27 2020-10-27 Southern Research Institute Nucleotides for the treatment of cancer
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
KR20240125709A (ko) 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
HUE065109T2 (hu) 2015-06-26 2024-05-28 Celgene Corp Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
CN108349968A (zh) 2015-07-28 2018-07-31 维奥梅生物科学私人有限公司 抗菌治疗剂和预防剂
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
SMT202100712T1 (it) 2015-08-17 2022-01-10 Kura Oncology Inc Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
BR112018003782A2 (pt) 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
JP6981973B2 (ja) 2015-10-01 2021-12-17 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
EP3362458A1 (en) 2015-10-16 2018-08-22 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3373916A1 (en) 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CN108883103A (zh) 2015-12-02 2018-11-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
CA3010286A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
WO2017120415A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
SG11201805779TA (en) 2016-01-08 2018-08-30 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
CN109069420A (zh) 2016-01-11 2018-12-21 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
MX376974B (es) 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
AU2017228371A1 (en) 2016-03-04 2018-09-13 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
MA44859A (fr) 2016-05-04 2019-03-13 Purdue Pharma Lp Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3029457A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
US20190282560A1 (en) 2016-07-18 2019-09-19 Pharmena S.A. 1-Methylnicotinamide for the Treatment of Diseases Associated With C-Reactive Protein
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
ES2932187T3 (es) 2016-09-07 2023-01-16 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
AU2017325844A1 (en) 2016-09-14 2019-03-07 Gilead Sciences, Inc. SYK inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combined treatment
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
US10918628B2 (en) 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
CN110352190A (zh) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
EP3529315B1 (en) 2016-10-21 2024-12-04 Da Zen Theranostics, Inc Near infrared (nir) dye cancer drug conjugated to a statin
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
TW201828932A (zh) 2016-11-09 2018-08-16 美商諾沃麥迪斯有限責任公司 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. METHOD OF TREATMENT OF CANCER
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
WO2018115888A1 (en) 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant
US10784877B2 (en) 2016-12-21 2020-09-22 Johnson & Johnson Vision Care, Inc. Extended period timer circuits for ophthalmic devices
JP7661008B2 (ja) 2017-01-04 2025-04-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
WO2018140671A1 (en) 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
PL3577119T3 (pl) 2017-02-06 2026-03-23 Spero Therapeutics, Inc. Postacie krystaliczne tebipenemu piwoksylu, zawierające je kompozycje, sposoby wytwarzania i sposoby zastosowania
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TWI738314B (zh) 2017-02-21 2021-09-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
EP4249503A3 (en) 2017-02-27 2023-12-20 Shattuck Labs, Inc. Vsig8-based chimeric proteins
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
JP7777915B2 (ja) 2017-03-27 2025-12-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを処置する組成物及び方法
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
PT3624796T (pt) 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
JP7237941B2 (ja) 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
WO2018222831A1 (en) 2017-05-31 2018-12-06 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019005874A1 (en) 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
CN111051305A (zh) 2017-08-22 2020-04-21 吉利德科学公司 治疗性杂环化合物
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
CN111356461A (zh) 2017-10-04 2020-06-30 加利福尼亚大学董事会 免疫调节性低聚糖
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
EP3710599B1 (en) 2017-11-13 2024-07-17 Gilead Sciences, Inc. Method for staging liver fibrosis in nash patients
EP3713916A1 (en) 2017-11-20 2020-09-30 Kiakos, Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
EP3727387A4 (en) 2017-12-18 2021-12-15 Sterngreene, Inc. PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
WO2019133901A1 (en) 2017-12-28 2019-07-04 Reviva Pharmaceuticals, Inc. Methods for treating pulmonary fibrosis
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
TW202406538A (zh) 2018-01-10 2024-02-16 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
JP7108041B2 (ja) 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
AU2019221765A1 (en) 2018-02-16 2020-09-10 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
JP2021513972A (ja) 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法
TW202000205A (zh) 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
WO2019165993A1 (zh) 2018-02-28 2019-09-06 上海汉都医药科技有限公司 一种药物组合物及其制备方法和应用
US11613517B2 (en) 2018-03-02 2023-03-28 Oregon Health & Science University Amide prodrugs of small molecule nuclear receptor modulators
JP7384815B2 (ja) 2018-03-22 2023-11-21 ザ チルドレンズ メディカル センター コーポレーション 肺の修復に関する方法および組成物
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
JP7125791B2 (ja) 2018-05-23 2022-08-25 シャンハイ ダブリュディー ファーマシューティカル カンパニー，リミティド 活性薬物成分の放出制御システムおよびその製造方法
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
AU2019297362B2 (en) 2018-07-06 2022-05-26 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
JP2021530541A (ja) 2018-07-27 2021-11-11 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. てんかんの治療方法
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
BR112021002261A2 (pt) 2018-08-07 2021-05-04 Firmenich Incorporated 2,2-dióxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-substituídos e formulações e usos dos mesmos
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
AU2019326265B2 (en) 2018-08-20 2025-07-24 Maggie's Pearl, Llc Methods for treating congenital disorders of glycosylation
EP3843846A4 (en) 2018-08-27 2022-09-07 Spinogenix, Inc. FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS
US12030858B2 (en) 2018-08-27 2024-07-09 Oregon Health & Science University PARP inhibitors for treating cancer and asthma
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP2022512541A (ja) 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Ｐｄ－１系キメラタンパク質を含む併用療法
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3873469A2 (en) 2018-11-01 2021-09-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
WO2020097437A1 (en) 2018-11-09 2020-05-14 The Children's Medical Center Corporation Methods and compositions for treating or preventing the development of food allergies
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
HRP20220295T1 (hr) 2018-11-19 2022-05-13 Global Blood Therapeutics, Inc. Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin
CA3120351A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
EP4233834A3 (en) 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
JP2022513159A (ja) 2018-11-29 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Ｒｎａを調節する方法
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
US11286243B2 (en) 2018-12-13 2022-03-29 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202038953A (zh) 2018-12-21 2020-11-01 美商庫拉腫瘤技術股份有限公司 鱗狀細胞癌之治療
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
SMT202500291T1 (it) 2019-01-31 2025-09-12 Spinogenix Inc Forme solide di un promotore di spinogenesi
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
JP7599176B2 (ja) 2019-02-06 2024-12-13 オレゴン ヘルス アンド サイエンス ユニバーシティ ビスホスホネート連結化合物
EP3920921A4 (en) 2019-02-07 2022-11-02 Alsatech, Inc. POLYVALENT EMOXYPIN DERIVATIVES
CA3129722A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
ES2988904T3 (es) 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
JP2022524887A (ja) 2019-03-22 2022-05-10 ドイチェス クレブスフォルシュングスツェントルム ヒストンデアセチラーゼ１０の新規の阻害剤
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
CA3134825A1 (en) 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20220004066A (ko) 2019-04-03 2022-01-11 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 약물 전달용 이온성 액체
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3139063A1 (en) 2019-05-03 2020-11-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2020227097A1 (en) 2019-05-03 2020-11-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
EP3978076A4 (en) 2019-06-03 2023-02-22 Irimajiri Therapeutics Inc. CYCLIC AMIDE COMPOUNDS FOR THE TREATMENT OF RABIES AND METHOD THEREOF
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP3986163A2 (en) 2019-06-19 2022-04-27 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US20220274921A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US11098002B2 (en) 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
EP4031534A1 (en) 2019-09-16 2022-07-27 Dice Alpha, Inc. Il-17a modulators and uses thereof
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
ES3053975T3 (en) 2019-10-01 2026-01-28 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
AU2020376792B2 (en) 2019-11-01 2025-10-02 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
CA3158963A1 (en) 2019-11-22 2021-05-27 Samir Mitragotri Ionic liquids for drug delivery
CA3157275C (en) 2019-11-26 2026-02-10 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
CN114980899A (zh) 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
WO2021113212A1 (en) 2019-12-02 2021-06-10 Celgene Corporation Therapy for the treatment of cancer
JP2023514725A (ja) 2020-02-24 2023-04-07 エグゼリクシス， インコーポレイテッド 化合物および使用方法
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
CA3169779A1 (en) 2020-02-28 2021-09-02 Andrew Mark Griffin Kcnt1 inhibitors and methods of use
WO2021183318A2 (en) 2020-03-09 2021-09-16 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
CA3176429A1 (en) 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
EP4126876A1 (en) 2020-04-01 2023-02-08 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
KR20230007441A (ko) 2020-04-28 2023-01-12 글로벌 블러드 테라퓨틱스, 인크. 페로포르틴 억제제로서의 시클로알킬 피리미딘
US20230226074A1 (en) 2020-04-28 2023-07-20 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
CA3181577A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
WO2021222196A1 (en) 2020-04-28 2021-11-04 President And Fellows Of Harvard College Methods and compositions relating to ionic liquid adjuvants
WO2021226033A1 (en) 2020-05-07 2021-11-11 President And Fellows Of Harvard College Hyaluronic acid drug conjugates
EP4157271A1 (en) 2020-05-29 2023-04-05 Boulder Bioscience LLC Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
CA3180060A1 (en) 2020-05-29 2021-12-02 Zongmin ZHAO Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US11311488B2 (en) 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2021262579A1 (en) 2020-06-23 2021-12-30 President And Fellows Of Harvard College Compositions and methods relating to combinatorial hyaluronic acid conjugates
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
CA3184852A1 (en) 2020-07-10 2022-01-13 Lida Katsimpardi Use of gdf11 to diagnose and treat anxiety and depression
EP4188542A1 (en) 2020-08-03 2023-06-07 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
IL300447A (en) 2020-08-12 2023-04-01 Actym Therapeutics Inc Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA
EP4196482B1 (en) 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
WO2022069701A1 (en) 2020-10-01 2022-04-07 Nogra Pharma Limited Methods of treating pulmonary fibrosis
JP7818011B2 (ja) 2020-10-16 2026-02-19 レラファイド バイオサイエンシーズ， インコーポレイテッド Ｍａｌｔ１モジュレーターおよびその使用
US20220133669A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TWI838670B (zh) 2020-12-22 2024-04-11 美商基利科學股份有限公司 經取代之吲哚化合物
TWI887510B (zh) 2020-12-22 2025-06-21 美商基利科學股份有限公司 6-取代之吲哚化合物
US20240117033A1 (en) 2021-01-15 2024-04-11 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
JP2024504728A (ja) 2021-01-26 2024-02-01 サイトケアズ （シャンハイ） インコーポレイテッド キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
ES3054393T3 (en) 2021-02-09 2026-02-03 Gilead Sciences Inc Thienopyrrole compounds
CA3211063A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
WO2022187573A1 (en) 2021-03-05 2022-09-09 President And Fellows Of Harvard College Methods and compositions relating to cell membrane hybridization and camouflaging
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
IL319926A (en) 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
CA3219786A1 (en) 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin
MX2023013514A (es) 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
WO2022265880A1 (en) 2021-06-16 2022-12-22 President And Fellows Of Harvard College Improved methods and compositions for drug delivery relating to ionic liquids
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US20240336565A1 (en) 2021-07-02 2024-10-10 Acer Therapeutics, Inc. Solid forms of osanetant
US20240391931A1 (en) 2021-08-05 2024-11-28 Bristol-Myers Squibb Company Tricyclic fused pyrimidine compounds for use as her2 inhibitors
US20240360411A1 (en) 2021-09-01 2024-10-31 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
WO2023034507A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
EP4396578A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for promoting adipocyte beiging
WO2023034506A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
US20240361301A1 (en) 2021-09-09 2024-10-31 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023039162A1 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating enteroendocrine cells
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023043827A2 (en) 2021-09-14 2023-03-23 Flagship Pioneering Innovations Vi, Llc Methods and compositions for perturbing monocyte and neutrophil lineages
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
CN120265625A (zh) 2021-09-24 2025-07-04 泽农医药公司 作为钠通道活化剂的吡啶基乙酰胺衍生物
CA3232237A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinyl derivatives as sodium channel activators
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
WO2023060134A1 (en) 2021-10-06 2023-04-13 Global Blood Therapeutics, Inc. Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
EP4412587A1 (en) 2021-10-08 2024-08-14 President And Fellows Of Harvard College Ionic liquids for drug delivery
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP4436974A1 (en) 2021-11-23 2024-10-02 Genentech, Inc. Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
EP4436975A1 (en) 2021-11-23 2024-10-02 Genentech, Inc. Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
CN118510783A (zh) 2021-11-23 2024-08-16 基因泰克公司 胆固醇生物合成的螺环调节剂及其用于促进髓鞘再生的用途
EP4441038A1 (en) 2021-11-30 2024-10-09 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
CR20240223A (es) 2021-12-03 2024-07-08 Gilead Sciences Inc Compuestos terapéuticos para la infección por el virus del vih
US12404262B2 (en) 2021-12-03 2025-09-02 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US20250041312A1 (en) 2021-12-10 2025-02-06 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023137178A1 (en) 2022-01-17 2023-07-20 Chandrasekhar Satishchandran Combinations of vitamin d3, niacinamide and lipoic acid for use in the maintenance of healthy blood glucose levels
WO2023147134A2 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
WO2023147135A1 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
CA3253352A1 (en) 2022-03-02 2023-09-07 Mitopower, Inc. NEW PROMEDICINAL PRODUCTS DERIVED FROM NICOTINIC ACID AND RIBOSE
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
KR20250006833A (ko) 2022-03-28 2025-01-13 아이소스테릭스, 인코포레이티드 라이신 아세틸 전이효소의 myst 계열의 억제제
AR128918A1 (es) 2022-03-30 2024-06-26 Biomarin Pharm Inc Oligonucleótidos que omiten el exón 51 de distrofina y sus aplicaciones
ES3064783T3 (en) 2022-03-31 2026-04-29 Rarefied Biosciences Inc Malt1 modulators and uses thereof
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CA3255290A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company NEW GSPT1 COMPOUNDS AND METHODS FOR USING THE NEW COMPOUNDS
KR20250006012A (ko) 2022-04-15 2025-01-10 셀진 코포레이션 약물에 대한 림프종의 반응성을 예측하는 방법 및 림프종을 치료하는 방법
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤
KR20250005348A (ko) 2022-04-26 2025-01-09 프락시스 프리시젼 메디신즈, 인크. 신경 장애의 치료
CA3251749A1 (en) 2022-05-02 2023-11-09 Esperion Therapeutics, Inc. MACROCYCLICAL INHIBITORS OF ATP CITRATE LYASE
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
KR20250006069A (ko) 2022-05-05 2025-01-10 바이오마린 파머수티컬 인크. 뒤시엔느 근이영양증을 치료하는 방법
US12522582B2 (en) 2022-05-20 2026-01-13 Gilead Sciences, Inc. Antiviral indolinyl compounds and uses thereof
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
EP4536222A1 (en) 2022-06-13 2025-04-16 EpicentRx, Inc. Compositions and methods for reducing adverse side effects in cancer treatment
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
CA3261875A1 (en) 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
US20260015356A1 (en) 2022-07-14 2026-01-15 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
EP4554955A1 (en) 2022-07-15 2025-05-21 Celloram, Inc. Celastrol derivatives
KR20250107797A (ko) 2022-08-17 2025-07-14 트랜센드 테라퓨틱스 인코퍼레이티드 페네틸아민 및 카티논 전구체
EP4580635A1 (en) 2022-08-31 2025-07-09 Taiho Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
JPWO2024071371A1 (2) 2022-09-30 2024-04-04
CA3268510A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions containing 3,3'-diindolmythane for treating a closed, non-bleeding head wound
AU2023365200A1 (en) 2022-10-18 2025-05-15 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
EP4608388A1 (en) 2022-10-25 2025-09-03 Starrock Pharma Inc. Combinatorial, and rotational combinatorial therapies for obesity and other diseases
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
EP4608838A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
IL320483A (en) 2022-10-28 2025-06-01 Basecamp Bio Inc Somatostatin receptor 2 agonists and uses thereof
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024097940A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Therapy for the treatment of cancer
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
EP4626865A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy
US11931224B1 (en) * 2022-12-19 2024-03-19 Robert Parker Tooth pod
CN120418231A (zh) 2022-12-30 2025-08-01 阿勒泰治疗公司 2-取代噻唑和苯并噻唑组合物和作为dux4抑制剂的方法
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof
WO2024220708A1 (en) 2023-04-19 2024-10-24 Gandeeva Therapeutics, Inc. Raf-mek protein complex modulators and methods of use thereof
EP4702143A2 (en) 2023-04-24 2026-03-04 BioMarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
WO2024233303A1 (en) 2023-05-05 2024-11-14 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
US20250051375A1 (en) 2023-05-31 2025-02-13 Gilead Sciences, Inc. Anti-hiv compounds
TW202515579A (zh) 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法
WO2025006568A2 (en) 2023-06-29 2025-01-02 Gilead Sciences, Inc. Mk2 inhibitors and methods of making and using the same
WO2025014963A1 (en) 2023-07-10 2025-01-16 Gandeeva Therapeutics, Inc. Inhibitors of p97 protein and methods of use
TW202517627A (zh) 2023-07-12 2025-05-01 美商瑞佩特治療公司 Ｃ－ｃ趨化因子受體４型拮抗劑的結晶型及其用途
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms
CN121752546A (zh) 2023-08-28 2026-03-27 基因泰克公司 胆固醇生物合成的叔吡啶基胺调节剂及其用于促进髓鞘再生的用途
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025085818A1 (en) 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder
WO2025085878A1 (en) 2023-10-20 2025-04-24 Altay Therapeutics, Inc. N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
WO2025096751A1 (en) 2023-11-01 2025-05-08 Esperion Therapeutics, Inc. Macrocyclic inhibitors of atp citrate lyase
WO2025102082A1 (en) 2023-11-10 2025-05-15 Altay Therapeutics, Inc. Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
TW202540079A (zh) 2023-11-17 2025-10-16 美商基利科學股份有限公司 抗病毒吲哚啉基化合物及其用途
WO2025104687A1 (en) 2023-11-17 2025-05-22 Gilead Sciences, Inc. Solid forms of a hsv helicase primase inhibitor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
TW202532072A (zh) 2023-12-08 2025-08-16 美商西建公司 治療多發性骨髓瘤之療法
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025212814A1 (en) 2024-04-03 2025-10-09 Gilead Sciences, Inc. Anti-hiv compounds
WO2025221809A1 (en) 2024-04-16 2025-10-23 Eluciderm Inc. 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2025240443A1 (en) 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections
WO2025240895A1 (en) 2024-05-17 2025-11-20 Siteone Therapeutics, Inc. SUBSTITUTED CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAIN
CZ2024224A3 (cs) 2024-05-30 2025-12-10 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. 1H-Pyrazolo[3,4-d]pyrimidinové ribonukleosidy s protinádorovou aktivitou pro terapeutické použití
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
WO2026015548A1 (en) 2024-07-08 2026-01-15 Convelo Therapeutics, Inc. Cyp51 inhibitors and method of using same
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors
US20260109692A1 (en) 2024-10-18 2026-04-23 UCB Biopharma SRL Kcnt1 inhibitors and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023499A (en) * 1910-09-20 1912-04-16 Ralcy Husted Bell Collapsible capsule.
US1279564A (en) * 1918-02-28 1918-09-24 Frederick Stearns & Company Method of forming medicine-injectors.
US1434531A (en) * 1919-01-29 1922-11-07 Lloyd W Cyrenius Ampullar container for liquids or semisolids
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US2962023A (en) * 1955-10-28 1960-11-29 Chappaz Gaston Medicator
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3574820A (en) * 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Also Published As

Publication number Publication date
JPS596843B2 (ja) 1984-02-15
CH578464A5 (2) 1976-08-13
NL163721C (nl) 1980-10-15
ES415568A1 (es) 1976-05-16
NL7307699A (2) 1973-12-07
JPS4961325A (2) 1974-06-14
IE39952B1 (en) 1979-02-14
FR2188568A5 (2) 1974-01-18
BR7304196D0 (pt) 1974-07-25
GB1415210A (en) 1975-11-26
AR199301A1 (es) 1974-08-23
IE39952L (en) 1973-12-05
NL163721B (nl) 1980-05-16
ZA733734B (en) 1974-06-26
IL42418A0 (en) 1973-07-30
US3845770A (en) 1974-11-05

Similar Documents

Publication Publication Date Title
IL42418A (en) An osmotic device for dispensing an active agent at a controlled rate
ZA739622B (en) Dispensing device
ZA734105B (en) Device for dispensing medicaments
JPS56127548A (en) Device for discharging article little by little
CA989781A (en) Aerosol dispensing device
CA996073A (en) Dispensing device
IL41876A0 (en) Fluid dispensing nozzle
AU6160973A (en) Dispensing
IL41185A (en) Electromagnetically controlled dispensing apparatus
IE37810L (en) Device for use with a pressurised dispensing container
ZA726621B (en) Distributing device for a sowing machine
CA976440A (en) Metering device for a liquid pump
IE38672L (en) Sustained release dispensing device
IL43208A0 (en) Seed dispensing device
YU78973A (en) Device for deposition welding
IE37349L (en) Dispensing apparatus
ZA739347B (en) Pressurised dispenser
IE38993L (en) Locating device for reinforcement members
GB1398579A (en) Liquid dispensers for animals
CA963577A (en) Liquid dispensing machine
AU487451B2 (en) Device for dispensing medicaments
CA897644A (en) Dispensing device
IL41519A0 (en) Device for dispensing ice
CA957267A (en) Unit dose packaging device
CA903151A (en) Pressurized dispensing device